Selective recognition of c-myc promoter G-quadruplex and down-regulation of oncogene c-myc transcription in human cancer cells by 3,8a-disubstituted indolizinone†

Fengmin Yang,ab Xin Sun,a Lixia Wang, a Qian Li,*a Aijiao Guan,a Gang Shenab and Yalin Tang*ab

C-myc promoter G-quadruplex is a very important target for developing anti-cancer drugs. However, highly selective recognition of DNA c-myc G-quadruplex with parallel configuration is also a very challenging problem. Here, we showed a new type of N-containing alkaloid, 3,8a-disubstituted indolizinone, which adopted a distorted configuration. 6-Methyl-3-(naphthalen-2-yl)-8a-(4-methylpyridin-2-yl)-indolizinone could selectively recognize DNA c-myc G-quadruplex leading to an obvious fluorescence enhancement by 11-fold, and meanwhile the G-quadruplex can be stabilized up to 90 °C. Further, it could down-regulate the transcription of oncogene c-myc in both human non-small cell line (A549) and human laryngeal epithelial cell line (Hep-2).

Introduction

The G-quadruplex structure formed by tandem guanine (G) nucleotides, which are incorporated in nucleic acid sequences, has illuminated a new role for DNA in biology. G-quadruplexes as one of the higher-order DNA and RNA structures have been identified in G-rich human telomeres and gene promoter regions. G-quadruplex as a therapeutic target has attracted a growing interest, due to its profound roles in a wide spectrum of diseases, such as cancer, diabetes and cardiovascular disorders. Several organic probes have been reported to recognize DNA G-quadruplex via diverse interaction modes. Stabilization of G-quadruplex structures in the promoter region of certain oncogenes is an emerging field in anticancer drug design. Human c-myc gene is one of these oncogenes, and G-quadruplexes have been proven to be the transcriptional controller of this gene.

Human c-myc gene or its product is a central regulator of cellular proliferation and cell growth, and over-expression of c-myc gene is related to various cancers. C-myc is the first and most extensively studied system of promoter G-quadruplex formation. The major G-quadruplex formed in the c-myc promoter is a parallel stranded structure with two G3NG3 single-nucleotide strand-reversal loops, and parallel-stranded structures are found to be more common in the promoter G-quadruplexes. Some known G-quadruplex-interactive compounds have become prospective anticancer agents that display relatively low cytotoxicity. In particular, Quarboxin, a first-in-class G-quadruplex-interactive drug reached phase 2 clinical trials, which was considered to be a c-myc G-quadruplex ligand at first. Quarboxin is a fluoroquinolone derivative with antineoplastic activity, and another known c-myc G-quadruplex ligand quinidine is a derivative of the natural product cryptolepine, and both of them are N-containing alkaloids. Here we reported a new type of N-containing alkaloid, indolizinone (Scheme 1), which can selectively recognize DNA c-myc G-quadruplex (DNA MycG4) and down-regulate oncogene c-myc.

Results

Indolizinones are N-heterocycles that have only recently appeared in the chemical literature, and to the best of our

Scheme 1 Structure of 6-methyl-3-(naphthalen-2-yl)-8a-(4-methylpyridin-2-yl)-indolizinone (indolizinone).
knowledge, any application of which wasn’t found to be reported. Recently, we firstly reported a copper-catalyzed domino reaction to construct functionalized 3,8α-disubstituted indolizinones, and this protocol was simple and highly efficient. In the solid state, 3,8α-disubstituted indolizinones adopted distorted configuration, and thus they provided no obviously strong fluorescence spectra in solution due to the lack of a larger conjugated π system. Most of DNA MycG4 ligands that have been previously reported are N-heterocycles with planar π systems, which can’t distinguish DNA MycG4 from other configurations of G-quadruplexes. In this report, we found 6-methyl-3-(naphthalen-2-yl)-8α-(4-methylpyridin-2-yl)-indolizione (indolizinone) here could selectively recognize DNA MycG4, leading to its greatly enhanced fluorescence intensity. We firstly compared the fluorescence intensity of indolizinone with five oligonucleotides of known G4 structures (Table S1†): intermolecular parallel configuration H7, intramolecular hybrid-type configuration M24, intramolecular anti-parallel configuration A24, intramolecular parallel configuration Kit and Myc, relative to the signal of indolizinone alone. As shown in Fig. 1, indolizinone itself at 4 μM gives a very weak fluorescence signal. While addition of 8 μM DNA MycG4, and then standing for 24 hours, the fluorescence signal of indolizinone lead to an obvious enhancement by 11-fold. Addition of other types of G-quadruplexes, such as intermolecular parallel type H7 led to 0.5-fold enhancement, and for intramolecular types, parallel DNA c-Kit 4.5-fold, hybrid-type M24 1.6-fold and anti-parallel type A24 2.5-fold, respectively. These results indicated that indolizinone preferred to recognize DNA MycG4.

Furthermore, fluorescence titrations were carried out to evaluate the binding constants of indolizinone with these five nucleic acid sequences (Fig. S1–S3†). A 1 : 1 binding model for indolizinone with DNA G-quadruplex was confirmed by the job’s plot analysis. The typical titration curves and fitting results according to the 1 : 1 binding model are presented. The binding constants for indolizinone with Myc and Kit are (9.91 ± 0.65) × 10^3 and (5.77 ± 1.60) × 10^3, respectively. The binding strength to Myc was obviously more strong than to Kit. In comparison with other intramolecular DNA G4s, the binding strength to A24 or M24 was much weaker, with binding constants (2.43 ± 0.37) × 10^4 and (1.88 ± 0.65) × 10^4, respectively. Of note, the binding strength to intermolecular H7 was very weak, and the binding constant is less than 10. As shown in Table 1, the trend of the binding constants is consistent with the IF/Fo values.

Then we subsequently performed this assay on a larger set of 25 nucleic acid sequences. Structures of these oligonucleotides have been characterized, and these oligonucleotides have been used in the G4-Fluorescence Intercalator Displacement (FID) assay. All sequences are listed in Table 2, and results are presented in Fig. 2. Fifteen of the 23 sequences are likely to form G4s. The fluorescence enhancements of indolizinone interacted with the parallel configuration G4 in the promoter region (c-myc, c-kit1, c-kit2, bel-2, AKT1, VAV1, 35B1, 27Kras) were 11-fold, 4.0-fold, 3.7-fold, 2.5-fold, 4.0-fold, 5.2-fold, 4.3-fold, and 3.4-fold, respectively. And the human telomeric DNA G-quadruplex 22Ag and 45Ag, which adopt anti-parallel configuration in the presence of K+ led to the fluorescence enhancements of indolizinone with the value IF/Fo 1.5-fold and 2.8-fold, respectively. And meanwhile, in the presence of another five G-quadruplex forming sequences (21CTA, TBA, Ceb25, CT4, CGG12), and other non-G-quadruplex DNA templates including single-stranded (G-tripl, dT30), double-stranded (ds26, 19AT, CGG12), and other non-G-quadruplex DNA templates including single-stranded (G-tripl, dT30), double-stranded (ds26, 19AT, dxt12, PS1c), stem-loop (GCdx), triplex, and trinucleotide (CGT12, CAG12), all these oligonucleotide sequences led to a IF/Fo < 2. Indolizinone showed higher response towards intramolecular DNA G-quadruplex with parallel configuration, especially most to DNA MycG4, comparing to other types of G-quadruplex and non-G-quadruplex templates. While it presented very weak response to intermolecular parallel G-quadruplex H7, just leading to 0.5-fold enhancement, probably attributing to its lack of loop-binding sites.

To evaluate the effect of indolizinone on the specific recognition of DNA MycG4, we applied circular dichroism to monitor the melting temperature (Tm) of DNA MycG4 in the presence of 1 equiv. molar ratio of indolizinone. The change of Tm in the folded and unfolded quadruplex structure upon interacting with ligand provides evidence of thermal stabilization of DNA structure. DNA MycG4 was incubated with indolizinone for 24 h, the Tm values for DNA MycG4 were calculated as shown in Fig. 3. Indolizinone shows the preferen ce to stabilize DNA MycG4 by raising the temperature up to 90 °C monitored at 265 nm. In the contrast, indolizinone shows a weak ability obviously to stabilize other types of G-quadruplexes (see Fig. S4†).

Based on the emission enhancement and the absorption spectral results, fluorescence intensity decay measurements

![Fig 1](image-url) Fluorescence intensity of indolizinone with five varied DNA G-quadruplexes in a 20 mM Tris HCl (40 mM K+, pH 7.0) solution at room temperature, E_x = 423 nm.

| Oligonucleotides | IF/Fo,a | Binding constants |
|------------------|---------|-------------------|
| Myc              | 11      | (9.91 ± 0.65) × 10^3 |
| Kit              | 4.5     | (5.77 ± 1.60) × 10^3 |
| A24              | 2.5     | (2.43 ± 0.37) × 10^4 |
| M24              | 1.6     | (1.88 ± 0.65) × 10^4 |
| H7               | 0.5     | <10                |

*a The concentrations of indolizinone and DNA G4 are 4 μM and 8 μM, respectively.
were conducted to demonstrate the strong binding of indolizinone with DNA MycG4. The fluorescence decay of indolizinone was fast (<1 ns) in solution due to the highly feasible torsional relation channel in the excited state. However, the lifetimes increased to the nanosecond level in the presence of DNA MycG4. As shown in Fig. 4, the fluorescence decay was much lower for indolizinone in the presence of 1 equiv. or 2 equiv. molar ratio of DNA MycG4, with the \( \tau \) value of 3.54 ns and 3.71 ns, respectively. This result indicated that the interaction between indolizinone and DNA MycG4 hinders the rotation of indolizinone and increases its lifetime.

![Fig. 2](image)

**Fig. 2** Dependence of indolizinone (4 \( \mu \)M) fluorescence intensity at 494 nm for a variety of DNA sequences (8 \( \mu \)M) in a 20 mM Tris HCl (40 mM K\(^+\), pH 7.0) solution.

were conducted to demonstrate the strong binding of indolizinone with DNA MycG4. The fluorescence decay of indolizinone was fast (<1 ns) in solution due to the highly feasible torsional relation channel in the excited state. However, the lifetimes increased to the nanosecond level in the presence of DNA MycG4. As shown in Fig. 4, the fluorescence decay was much lower for indolizinone in the presence of 1 equiv. or 2 equiv. molar ratio of DNA MycG4, with the \( \tau \) value of 3.54 ns and 3.71 ns, respectively. This result indicated that the interaction between indolizinone and DNA MycG4 hinders the rotation of indolizinone and increases its lifetime.

![Fig. 3](image)

**Fig. 3** CD melting profile of 4 \( \mu \)M DNA MycG4 alone or in the presence of 1 equiv. molar ratio of indolizinone in a 20 mM Tris HCl (40 mM K\(^+\), pH 7.0) solution.
Oncogene c-myc encodes an important transcriptional regulator c-myc protein, which is involved in cell proliferation, senescence, and apoptosis.\(^1\) Because c-myc promoter region contains G-quadruplex forming G-rich sequence, its binding with indolizinone could increase its stability resulting in down-regulation of oncogene c-myc transcription, which would be critical in understanding the effect of indolizinone on oncogene c-myc, two cancer cell lines with different translocation break points within the oncogene c-myc were tested. Human non-small cell line (A549) and human laryngeal epithelial cell line (Hep-2) were obtained from the National Infrastructure of Cell Line Resource (Beijing, China). As shown in Fig. 5, indolizinone could down-regulate the transcription of oncogene c-myc in both A549 and Hep-2 cells, after treated with indolizinone at 0.5, 1.0, 2.0, 4.0, and 8.0 \(\mu\)M for 48 h. The total RNA was extracted and reverse transcribed to cDNA. This cDNA was then used as a template for specific RCR amplification of the c-myc sequence and controlled by \(\beta\)-actin.

**Conclusions**

Indolizinones are N-heterocycles that have only recently appeared in the chemical literature, which can be prepared from the simple and achievable starting materials efficiently. Here, we firstly reported the indolizinone has the potential ability to recognize DNA MycG4 by fluorescence spectra and varied temperature CD spectra. When indolizinone complexed with DNA MycG4 in the ratio of 1 : 2, and thus it can give an obvious fluorescence enhancement by 11-fold, and meanwhile the DNA MycG4 can be stabilized up to 90°C. Further, we found indolizinone could down-regulate the transcription of oncogene c-myc in both of human non-small cell line (A549) and human laryngeal epithelial cell line (Hep-2) by real-time RT-PCR experiment. We believed that indolizinone will have a potential application in the exploration of anticancer drugs.

**Conflicts of interest**

There are no conflicts to declare.

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (Grant No. 21472197, 21675162, 21778058, 21302188), the Beijing Natural Science Foundation (Grant No. 7172248), Funding for open access charge: The National Natural Science Foundation of China (21603071).

**Notes and references**

1 Selected recent reviews, see: (a) Q. Cao, Y. Li, E. Freisinger, P. Z. Qin, R. K. O. Sigel and Z. W. Mao, *Inorg. Chem. Front.*, 2017, 4, 10–32; (b) Y. W. Chen and D. Z. Yang, *Curr. Protoc. Nucleic Acid Chem.*, 2012, 17.5.1–17.5.17; (c) K. M. Miller and R. Rodriguez, *Expert Rev. Clin. Pharmacol.*, 2011, 4, 139–142; (d) J. T. Davis, *Angew. Chem., Int. Ed.*, 2004, 43, 668–698; (e) L. H. Hurley, R. T. Wheelhouse, D. Sun, S. M. Kerwin, M. Salazar, O. Y. Fedoroff, F. X. Han, H. Y. Han, E. Izbiacka and D. Von Hoff, *Pharmacol. Ther.*, 2000, 85, 141–158; (f) T. M. Ou, Y. J. Lu, J. H. Tan, Z. S. Huang, K. Y. Wong and L. Q. Gu, *ChemMedChem*, 2008, 3, 690–713.

2 Q. Li, J. F. Xiang, Q. F. Yang, H. X. Sun, A. J. Guan and Y. L. Tang, *Nucleic Acids Res.*, 2013, 41, D1115–D1123.

3 Selected organic probes: (a) J. Mohanty, N. Barooah, V. Dhamodharan, S. Harikrishna, P. I. Pradeepkumar and A. C. Bhasikuttan, *J. Am. Chem. Soc.*, 2013, 135, 367–376; (b) J. Dai, M. Carver, L. H. Hurley and D. Z. Yang, *J. Am. Chem. Soc.*, 2011, 133, 17673–17680; (c) D. Koirala, etc.
S. Dhakal, B. Ashbridge, Y. Sannohe, R. Rodriguez, H. Sugiyama, S. Balasubramanian and H. Mao, *Nat. Chem.*, 2011, 3, 782–787; (d) S. J. Xu, Q. Li, J. F. Xiang, Q. F. Yang, H. X. Sun, A. J. Guan, L. X. Wang, Y. Liu, L. J. Yu, Y. H. Shi, H. B. Chen and Y. L. Tang, *Nucleic Acids Res.*, 2015, 43, 9575–9586; (e) R. Haudecoeur, L. Stefan, F. Denat and D. Monchaud, *J. Am. Chem. Soc.*, 2013, 135, 550–553; (f) M. Wang, Z. Mao, T. S. Kang, C. Y. Wong, J. L. Mergny, C. H. Leung and D. L. Ma, *Chem. Sci.*, 2016, 7, 2516.

4 (a) R. V. Brown, T. Wang, V. R. Chappeta, G. H. Wu, B. Onel, R. Chawla, H. Quijada, S. M. Camp, E. T. Chiang, Q. R. Lassiter, C. Lee, S. Phanse, M. A. Turnidge, P. Zhao, J. G. Garcia, V. Gokhale, D. Z. Yang and L. H. Hurley, *J. Am. Chem. Soc.*, 2017, 139, 7456–7475; (b) T. M. Ou, Y. J. Lu, C. Zhang, Z. S. Huang, X. D. Wang, J. H. Tan, Y. Chen, D. L. Ma, K. Y. Wong and J. C. Tang, *J. Med. Chem.*, 2011, 54, 5671–5679.

5 L. M. Resar, E. Emison, S. Kim, Q. Li, J. E. Prescott, D. Wonsey and K. Zeller, *Exp. Cell Res.*, 1999, 253, 63–77.

6 D. Drygin, A. Siddiqui-Jain, S. O’Brien, M. Schwebe, A. Lin, J. Bliesath, C. B. Ho, C. Proffitt, K. Trent, J. P. Whitten, J. K. C. Lim, D. Von Hoff, K. Anderes and W. G. Rice, *Cancer Res.*, 2009, 69, 7653–7661.

7 A. R. H. Narayan and R. Sarpong, *Org. Biomol. Chem.*, 2012, 10, 70, and references cited therein.

8 B. Q. Hu, L. X. Wang, G. Shen, Y. L. Tang and L. Yang, *RSC Adv.*, 2015, 5, 100097.

9 (a) V. Gabelica, R. Maeda, T. Fujimoto, H. Yaku, T. Murashima, N. Sugimoto and D. Miyoshi, *Biochemistry*, 2013, 52, 5620–5628; (b) A. R. Faverie, A. Guédin, A. Bedrat, L. A. Yatsuny and J. L. Mergny, *Nucleic Acids Res.*, 2014, 1–8; (c) S. J. Xu, Q. Li, J. F. Xiang, Q. F. Yang, H. X. Sun, A. J. Guan, L. X. Wang, Y. Liu, L. J. Yu, Y. H. Shi, H. B. Chen and Y. L. Tang, *Sci. Rep.*, 2016, 6, 24793–24801.

10 L. X. Wang, Q. Shang, Q. Li, J. F. Xiang, Y. Liu, A. J. Guan, H. X. Sun, L. J. Yu and Y. L. Tang, *Tetrahedron*, 2015, 71, 4982.

11 T. Simonsson and M. Henriksson, *Biochem. Biophys. Res. Commun.*, 2002, 290, 11–15.

12 T. M. Ou, J. Lin, Y. J. Lu, J. Q. Hou, J. H. Tan, S. H. Chen, Z. Li, Y. P. Li, D. Li, L. Q. Gu and Z. S. Huang, *J. Med. Chem.*, 2011, 54, 5671–5679.